/ 1-800-LUNGUSA
Control Program Funding:FY2013 State Funding for
Medications: All health plans cover NRT Patch
Percentage of CDC Recommended Level: 64.7%
(Zyban) and Varenicline (Chantix) varies by
*Includes tobacco prevention and cessation funding provided
to states from the Centers for Disease Control and Prevention
and U.S. Food and Drug Administration.
Counseling: All health plans required to cover
counseling; type of counseling covered varies
Barriers to Coverage: Barriers to coverage vary
recommends an investment of $10.53/smoker
Recreational/Cultural Facilities: Prohibited
*Due to current data on tobacco cessation coverage for state
employees being unavailable, Hawaii was graded based on
cessation coverage under Medicaid and quitline investment per
Citation: HAW. REV. STAT. §§ 328J-1 to 328J-15
smoker only. **Barriers could include: Limits on duration, annual or
lifetime limits on quit attempts, requiring prior authorization,
requiring co-payments, requiring using one or more cessation
treatments before using others and/or requiring the use of
The American Lung Association in Hawaii continues its leadership role in
effects of secondhand smoke. The Lung Association
continues its collaboration with the Coalition for
Tobacco Free Hawaii on bills in the legislature to increase tobacco taxes, increase access to cessation
Smoking Attributable Lung Cancer Deaths:
resources and protect Hawaii’s comprehensive
Smoking Attributable Respiratory Disease Deaths: 226
Adult smoking rate is taken from CDC’s 2011 Behavioral Risk Factor Sur-
During the 2012 legislative session, House Bill 2306
veillance System. High school and middle school smoking rates are taken
was introduced which would have allowed smoking
from the 2011 Hawaii Youth Tobacco Survey.
again in bars and nightclubs. A poll conducted by
Health impact information is taken from the Smoking Attributable Mortality,
Morbidity and Economic Costs (SAMMEC) software. Smoking attributable
Qmark found that 87 percent of Hawaii residents
deaths reflect average annual estimates for the period 2000-2004 and
surveyed supported the smokefree workplace law.
are calculated for persons aged 35 years and older. They do not take into
account deaths from burns or secondhand smoke. Respiratory diseases
This strong support, along with overwhelming efforts
include pneumonia, influenza, bronchitis, emphysema and chronic airway
obstruction. The estimated economic impact of smoking is based on
of grassroot advocates contacting legislators resulted
smoking-attributable health care expenditures in 2004 and the average
annual productivity losses for the period 2000-2004.
The Lung Association continues to advocate for
funding for Hawaii’s successful tobacco prevention
and control programs. Dollars received through the Master Settlement Agreement with the tobacco
industry are allocated to the Tobacco Settlement
Special Fund. A portion of this fund is used by
the Department of Health for health promotion
and chronic disease prevention programs, includ-
ing tobacco control programs. Another portion is deposited into the Tobacco Prevention and Control Trust Fund which provides funding for the Hawaii Quitline, media campaigns and community interven-tion grants.
Facing continuing budgetary challenges, legisla-tors unfortunately chose to divert money from the Tobacco Prevention and Control Trust Fund to the general revenue budget for two years back in 2011. Due to this diversion, the tobacco program realized a slight decrease in funding this budget year (fiscal year 2013) from last year.
The American Lung Association in Hawaii will con-tinue educational outreach on the vital importance of funding tobacco prevention and cessation programs.
American Lung Association State of Tobacco Control 2013
DEPARTMENT OF HEALTH AND HUMAN SERVICES CENTERS FOR MEDICARE & MEDICAID SERVICES RESIDENT CENSUS AND CONDITIONS OF RESIDENTS Independent Assist of One or Two Staff Dependent A. Bowel/Bladder Status B. Mobility F94 ____ With indwelling or external catheter F100 ____ Bedfast all or most of time F95 Of the total number of residents with catheters, F101 ____ In a cha
Mon February 9, 2009 ROXRO Announces FDA Accepts for Review NDA for ROX-888 for the Management of Acute Moderate to Severe Pain; Potential to be the First Non-narcotic Intranasal Analgesic MENLO PARK, CA (February 06, 2009) ROXRO announced today that the U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for its lead investigational prescription dru